Comparative Study
. 1982 Mar-Apr;4(2):593-601.
doi: 10.1093/clinids/4.2.593.
- PMID: 6981175
- DOI: 10.1093/clinids/4.2.593
Comparative Study
Trimethoprim-sulfamethoxazole and trimethoprim alone for prophylaxis of infection in granulocytopenic patients
M Gurwith et al. Rev Infect Dis. 1982 Mar-Apr.
Abstract
Prophylactic trimethoprim-sulfamethoxazole (TMP-SMZ) has been shown to reduce the incidence of fever, parenteral antibiotic usage, and infections with gram-negative bacteria in hospitalized patients with neutropenia. Furthermore, TMP-SMZ was found to be equivalent to or better than oral, nonabsorbable antibiotics in direct comparisons and to have an additive effect when given together with other oral, nonabsorbable antibiotics. Adults given TMP-SMZ continuously had fewer readmissions for infection than did controls given TMP-SMZ only while hospitalized. TMP-SMZ used continuously in children with acute leukemia was effective in preventing bacterial and Pneumocystis carinii infections. For prophylaxis in granulocytopenic patients, TMP appeared equivalent to TMP-SMZ both in efficacy and incidence of side effects. However, TMP was less effective in suppressing gastrointestinal flora, including TMP-resistant gram-negative rods. Thus, TMP-SMZ has some role in preventing infections in high-risk patients, but further studies, especially comparisons with untreated patients may still be required. TMP used alone offers little advantage and has the theoretical disadvantage of not preventing infections caused by P. carinii or TMP-resistant gram-negative bacteria.
Similar articles
Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. EORTC International Antimicrobial Therapy Project Group.
[No authors listed] [No authors listed] J Infect Dis. 1984 Sep;150(3):372-9. doi: 10.1093/infdis/150.3.372. J Infect Dis. 1984. PMID: 6384377 Clinical Trial.
Trimethoprim-sulfamethoxazole therapy for Pneumocystis carinii pneumonitis in children.
Hughes WT. Hughes WT. Rev Infect Dis. 1982 Mar-Apr;4(2):602-7. doi: 10.1093/clinids/4.2.602. Rev Infect Dis. 1982. PMID: 6981176 Clinical Trial.
Use of trimethoprim-sulfamethoxazole singly and in combination with other antibiotics in immunocompromised patients.
Young LS, Hindler J. Young LS, et al. Rev Infect Dis. 1987 Mar-Apr;9 Suppl 2:S177-83. doi: 10.1093/clinids/9.supplement_2.s177. Rev Infect Dis. 1987. PMID: 3554456 Review.
Use of trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonitis in patients with acquired immunodeficiency syndrome.
Wofsy CB. Wofsy CB. Rev Infect Dis. 1987 Mar-Apr;9 Suppl 2:S184-94. doi: 10.1093/clinids/9.supplement_2.s184. Rev Infect Dis. 1987. PMID: 3554457 Review.
Cited by
Trimethoprim- sulfamethoxazole: pharmacokinetics, clinical uses, and adverse reactions.
Kielhofner MA. Kielhofner MA. Tex Heart Inst J. 1990;17(2):86-93. Tex Heart Inst J. 1990. PMID: 15227389 Free PMC article. No abstract available.
Comparative in vitro activity of norfloxacin against urinary tract pathogens.
Haase D, Urias B, Harding G, Ronald A. Haase D, et al. Eur J Clin Microbiol. 1983 Jun;2(3):235-41. doi: 10.1007/BF02029524. Eur J Clin Microbiol. 1983. PMID: 6224679
Role of anaerobic flora in the translocation of aerobic and facultatively anaerobic intestinal bacteria.
Wells CL, Maddaus MA, Reynolds CM, Jechorek RP, Simmons RL. Wells CL, et al. Infect Immun. 1987 Nov;55(11):2689-94. doi: 10.1128/iai.55.11.2689-2694.1987. Infect Immun. 1987. PMID: 3666959 Free PMC article.